ABSTRACT
Since the concept of IgG4-related disease (IgG4-RD) was proposed, that diagnosis has been considered in idiopathic fibroinflammatory diseases in various organs, particularly in cases with multi-organ involvement. We have recently encountered three cases of fibrosing disease of uncertain etiology with shared microscopic appearances. Case 1 (56-year-old man) had an irregular mass at the base of mesentery. Case 2 (29-year-old woman) presented with obstructive jaundice due to an ill-defined mass at the hepatic hilum and two lung nodules. Case 3 (53-year-old man) had multiple solid nodules in the mediastinum, peritoneum, retroperitoneum, and mesentery; he also had diffuse irregular narrowing of the intra- and extra-hepatic bile ducts in keeping with sclerosing cholangitis. Serum IgG4 concentrations were not elevated. Biopsies from the nodular lesions showed extensive hyalinizing fibrosis with an only focal lymphoplasmacytic infiltrate. Thick collagenous bundles are arranged in an irregular or partly whorl pattern. Typical storiform fibrosis or obliterative phlebitis was not observed. The number of IgG4-positive plasma cells was <10 cells/high-power field; the ratio of IgG4/IgG-positive plasma cells was <30%. After the histological diagnosis of sclerosing mesenteritis, pulmonary hyalinizing granuloma, and mediastinal fibrosis was made, they were treated with a trial of steroids, but none showed a significant response. In conclusion, a hyalinizing fibrotic condition can occur at various anatomical sites. They have shared microscopic findings, and are steroid-resistant. Although the clinical presentation may mimic IgG4-RD, the two conditions are likely distinct. We would propose a diagnostic term of 'idiopathic hyalinizing fibrosclerosis' for this under-recognized, rare, systemic condition.
Subject(s)
Fibrosis , Immunoglobulin G4-Related Disease , Immunoglobulin G , Humans , Male , Female , Immunoglobulin G4-Related Disease/pathology , Immunoglobulin G4-Related Disease/drug therapy , Immunoglobulin G4-Related Disease/diagnosis , Immunoglobulin G4-Related Disease/complications , Immunoglobulin G4-Related Disease/immunology , Middle Aged , Fibrosis/pathology , Immunoglobulin G/blood , Adult , Sclerosis/pathology , Diagnosis, Differential , Drug Resistance , Cholangitis, Sclerosing/pathology , Cholangitis, Sclerosing/immunology , Cholangitis, Sclerosing/drug therapy , Cholangitis, Sclerosing/diagnosis , Biopsy , Steroids/therapeutic use , Biomarkers/blood , Biomarkers/analysis , ImmunohistochemistryABSTRACT
Cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), result from an impairment of bile flow that leads to the hepatic retention of bile acids, causing liver injury. Until recently, the only approved treatments for PBC were ursodeoxycholic acid (UDCA) and obeticholic acid (OCA). While these therapies slow the progression of PBC in the early stage of the disease, approximately 40% of patients respond incompletely to UDCA, and advanced cases do not respond. UDCA does not improve survival in patients with PSC, and patients often have dose-limiting pruritus reactions to OCA. Left untreated, these diseases can progress to fibrosis and cirrhosis, resulting in liver failure and the need for transplantation. These shortcomings emphasize the urgent need for alternative treatment strategies. Recently, nuclear hormone receptors have been explored as pharmacological targets for adjunct therapy because they regulate enzymes involved in bile acid metabolism and detoxification. In particular, the peroxisome proliferator-activated receptor (PPAR) has emerged as a therapeutic target for patients with PBC or PSC who experience an incomplete response to UDCA. PPARα is predominantly expressed in the liver, and it plays an essential role in the regulation of cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes, both of which are critical enzyme families involved in the regulation of bile acid metabolism and glucuronidation, respectively. Importantly, PPARα agonists, e.g., fenofibrate, have shown therapeutic benefits in reducing elevated markers of cholestasis in patients with PBC and PSC, and elafibranor, the first PPAR (dual α, ß/δ) agonist, has been FDA-approved for the second-line treatment of PBC. Additionally, newer PPAR agonists that target various PPAR isoforms (ß/δ, γ) are under development as an adjunct therapy for PBC or PSC, although their impact on glucuronidation pathways are less characterized. This review will focus on PPAR-mediated bile acid glucuronidation as a therapeutic pathway to improve outcomes for patients with PBC and PSC.
Subject(s)
Bile Acids and Salts , Humans , Bile Acids and Salts/metabolism , Peroxisome Proliferator-Activated Receptors/metabolism , Peroxisome Proliferator-Activated Receptors/agonists , Cholestasis/metabolism , Cholestasis/drug therapy , Animals , Liver Cirrhosis, Biliary/metabolism , Liver Cirrhosis, Biliary/drug therapy , Cholangitis, Sclerosing/drug therapy , Cholangitis, Sclerosing/metabolismABSTRACT
BACKGROUND: Novel noninvasive predictors of disease severity and prognosis in primary sclerosing cholangitis (PSC) are needed. This study evaluated the ability of extracellular matrix remodeling markers to diagnose fibrosis stage and predict PSC-related fibrosis progression and clinical events. METHODS: Liver histology and serum markers of collagen formation (propeptide of type III collagen [Pro-C3], propeptide of type IV collagen, propeptide of type V collagen), collagen degradation (type III collagen matrix metalloproteinase degradation product and type IV collagen matrix metalloproteinase degradation product), and fibrosis (enhanced liver fibrosis [ELF] score and its components [metalloproteinase-1, type III procollagen, hyaluronic acid]) were assessed in samples from baseline to week 96 in patients with PSC enrolled in a study evaluating simtuzumab (NCT01672853). Diagnostic performance for advanced fibrosis (Ishak stages 3-6) and cirrhosis (Ishak stages 5-6) was evaluated by logistic regression and AUROC. Prognostic performance for PSC-related clinical events and fibrosis progression was assessed by AUROC and Wilcoxon rank-sum test. RESULTS: Among 234 patients, 51% had advanced fibrosis and 11% had cirrhosis at baseline. Baseline Pro-C3 and ELF score and its components provided moderate diagnostic ability for discrimination of advanced fibrosis (AUROC 0.73-0.78) and cirrhosis (AUROC 0.73-0.81). Baseline Pro-C3, ELF score, and type III procollagen provided a moderate prognosis for PSC-related clinical events (AUROC 0.70-0.71). Among patients without cirrhosis at baseline, median changes in Pro-C3 and ELF score to week 96 were higher in those with than without progression to cirrhosis (both p < 0.001). CONCLUSIONS: Pro-C3 correlated with fibrosis stage, and Pro-C3 and ELF score provided discrimination of advanced fibrosis and cirrhosis and predicted PSC-related events and fibrosis progression. The results support the clinical utility of Pro-C3 and ELF score for staging and as prognostic markers in PSC.
Subject(s)
Antibodies, Monoclonal, Humanized , Biomarkers , Cholangitis, Sclerosing , Disease Progression , Extracellular Matrix , Liver Cirrhosis , Humans , Cholangitis, Sclerosing/drug therapy , Cholangitis, Sclerosing/blood , Cholangitis, Sclerosing/pathology , Male , Female , Biomarkers/blood , Prognosis , Adult , Liver Cirrhosis/blood , Liver Cirrhosis/drug therapy , Liver Cirrhosis/etiology , Antibodies, Monoclonal, Humanized/therapeutic use , Middle Aged , Extracellular Matrix/pathology , Severity of Illness Index , Hyaluronic Acid/blood , Liver/pathologyABSTRACT
Primary Sclerosing Cholangitis (PSC) is a progressive cholestatic liver disease with no licensed therapies. Previous Genome Wide Association Studies (GWAS) have identified genes that correlate significantly with PSC, and these were identified by systematic review. Here we use novel Network Proximity Analysis (NPA) methods to identify already licensed candidate drugs that may have an effect on the genetically coded aspects of PSC pathophysiology.Over 2000 agents were identified as significantly linked to genes implicated in PSC by this method. The most significant results include previously researched agents such as metronidazole, as well as biological agents such as basiliximab, abatacept and belatacept. This in silico analysis could potentially serve as a basis for developing novel clinical trials in this rare disease.
Subject(s)
Cholangitis, Sclerosing , Cholangitis, Sclerosing/drug therapy , Cholangitis, Sclerosing/genetics , Humans , Genome-Wide Association Study , Models, TheoreticalABSTRACT
BACKGROUND: According to the new AASLD Practice Guidance, all patients with primary sclerosing cholangitis (PSC) should be considered for participation in clinical trials. However, PSC's rarity has posed challenges to characterizing patient interest in trial participation and identifying predictors of patient willingness to participate in drug trials. METHODS: PSC Partners Seeking a Cure developed the "Our Voices" survey to inform the development of the Externally-Led Patient-Focused Drug Development Forum, an FDA initiative to capture patient experiences and perspectives on drug development. RESULTS: Of 797 survey respondents from over 30 countries, 536 (67%) identified slowing disease progression as the most important outcome. Eighty-nine percent identified their hepatologist/gastroenterologist as someone they would approach for advice about trials. Although 61% reported being willing to participate in drug trials, only 26% had ever been asked to participate. Notable barriers to trial involvement included unknown long-term risks (71%), long travel times to the study center (32%), and a liver biopsy requirement (27%). On multivariable logistic regression, pruritus (OR 1.62, 95% CI: 1.09-2.40, p = 0.017) was positively associated with willingness to participate in disease-modifying therapy trials, while jaundice (OR 0.34, 95% CI: 0.19-0.61, p < 0.001) and inflammatory bowel disease (OR 0.64, 95% CI: 0.42-0.98, p = 0.038) were negatively associated. Pruritus (OR 2.25, 95% CI: 1.50-3.39, p < 0.001) was also independently associated with willingness to participate in symptom treatment trials. CONCLUSIONS: Most patients with PSC report interest in participating in clinical trials, but few have been asked to participate. Referral of patients with PSC by their hepatologist/gastroenterologist to clinical trials and patient education on trial participation are vital to closing the gap between trial interest and participation. Pruritus may serve as a key indicator of patient interest in trial participation.
Subject(s)
Cholangitis, Sclerosing , Clinical Trials as Topic , Drug Development , Patient Participation , Humans , Cholangitis, Sclerosing/drug therapy , Cholangitis, Sclerosing/complications , Male , Female , Adult , Middle Aged , Surveys and Questionnaires , Disease ProgressionABSTRACT
INTRODUCTION: Primary sclerosing cholangitis (PSC) is a bile duct disorder characterized by ductular reaction, hepatic inflammation, and liver fibrosis. The pathogenesis of PSC is still undefined, and treatment options for patients are limited. Previous clinical trials evaluated drug candidates targeting various cellular functions and pathways, such as bile acid signaling and absorption, gut bacteria and permeability, and lipid metabolisms. However, most of phase III clinical trials for PSC were disappointing, except vancomycin therapy, and there are still no established medications for PSC with efficacy and safety confirmed by phase IV clinical trials. AREAS COVERED: This review summarizes the currently ongoing or completed clinical studies for PSC, which are phase II or further, and discusses therapeutic targets and strategies, limitations, and future directions and possibilities of PSC treatments. A literature search was conducted in PubMed and ClinicalTrials.gov utilizing the combination of the searched term 'primary sclerosing cholangitis' with other keywords, such as 'clinical trials,' 'antibiotics,' or drug names. Clinical trials at phase II or further were included for consideration. EXPERT OPINION: Only vancomycin demonstrated promising therapeutic effects in the phase III clinical trial. Other drug candidates showed futility or inconsistent results, and the search for novel PSC treatments is still ongoing.
Subject(s)
Cholangitis, Sclerosing , Cholangitis, Sclerosing/drug therapy , Humans , Animals , Anti-Bacterial Agents/therapeutic use , Vancomycin/therapeutic useABSTRACT
OBJECTIVES: Immune-related adverse event-sclerosing cholangitis caused by treatment with immune checkpoint inhibitors is rare, and the diagnostic criteria and treatment strategy remain unclear. In this study, we confirmed the clinicopathological features of immune-related adverse event-sclerosing cholangitis and clarified its diagnosis and appropriate management. METHODS: We retrospectively evaluated 10 patients diagnosed with immune-related adverse event-sclerosing cholangitis and identified by electronic database searches. RESULTS: Blood tests revealed liver dysfunction with a predominance of biliary tract enzymes in all patients; however, jaundice was present in only one patient. Contrast-enhanced computed tomography revealed diffuse hypertrophy of the extrahepatic bile duct wall as the most frequent finding; however, endoscopic retrograde cholangiopancreatography showed various imaging features, such as the pruned-tree appearance of intrahepatic bile ducts, in all patients. Transpapillary bile duct biopsy showed inflammatory cell infiltration using immunostaining, with a predominance of cluster of differentiation 8-positive T cells in 63% of the cases. Initial steroid therapy was effective in two cases. Mycophenolate mofetil and tacrolimus were used in steroid-refractory cases. Although six patients showed improvements, all of the remaining patients died owing to immune-related adverse event-sclerosing cholangitis. CONCLUSIONS: Various bile duct imaging findings of immune-related adverse event-sclerosing cholangitis were revealed; transpapillary bile duct biopsy may be useful in the diagnosis of immune-related adverse event-sclerosing cholangitis. Despite the combination of multiple immunosuppressive agents, prognosis of immune-related adverse event-sclerosing cholangitis remains poor. Longer follow-up and larger clinical studies are necessary to establish its treatment strategy.
Subject(s)
Cholangitis, Sclerosing , Immune Checkpoint Inhibitors , Humans , Cholangitis, Sclerosing/chemically induced , Cholangitis, Sclerosing/diagnostic imaging , Cholangitis, Sclerosing/pathology , Cholangitis, Sclerosing/immunology , Cholangitis, Sclerosing/drug therapy , Male , Immune Checkpoint Inhibitors/adverse effects , Female , Retrospective Studies , Middle Aged , Aged , Tomography, X-Ray Computed , Adult , Aged, 80 and overSubject(s)
Anti-Bacterial Agents , Cholangitis, Sclerosing , Inflammatory Bowel Diseases , Practice Guidelines as Topic , Vancomycin , Humans , Cholangitis, Sclerosing/drug therapy , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/complications , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Vancomycin/administration & dosage , Vancomycin/therapeutic use , Administration, OralABSTRACT
BACKGROUND: Primary sclerosing cholangitis is a progressive inflammatory liver disease characterized by biliary and liver fibrosis. Vascular adhesion protein-1 (VAP-1) is important in the inflammatory process driving liver fibrosis. We evaluated the safety and efficacy of VAP-1 blockade with a monoclonal antibody (timolumab, BTT1023) in patients with primary sclerosing cholangitis. METHODS: BUTEO was a prospective, single-arm, open-label, multicenter, phase II trial, conducted in 6 centers in the United Kingdom. Patients with primary sclerosing cholangitis aged 18-75 years had an alkaline phosphatase value of >1.5 times the upper limit of normal. The dose-confirmatory stage aimed to confirm the safety of timolumab through the incidence of dose-limiting toxicity and sufficient trough levels of circulating antibody to block VAP-1 function. The primary outcome of the dose-expansion portion of the trial was patient's response to timolumab at day 99, as measured by a reduction in serum alkaline phosphatase by 25% or more from baseline to day 99. RESULTS: Twenty-three patients were recruited: 7 into the initial dose-confirmatory stage and a further 16 into an expansion stage. Timolumab (8 mg/kg) was confirmed to be safe for the duration of administration with sufficient circulating levels. Only 2 of the 18 evaluable patients (11.1%) achieved a reduction in alkaline phosphatase levels of 25% or more, and both the proportion of circulating inflammatory cell populations and biomarkers of fibrosis remained unchanged from baseline. CONCLUSIONS: The BUTEO trial confirmed 8 mg/kg timolumab had no short-term safety signals and resulted in sufficient circulating levels of VAP-1 blocking timolumab. However, the trial was stopped after an interim assessment due to a lack of efficacy as determined by no significant change in serum liver tests.
Subject(s)
Amine Oxidase (Copper-Containing) , Cell Adhesion Molecules , Cholangitis, Sclerosing , Humans , Male , Female , Middle Aged , Adult , Cholangitis, Sclerosing/drug therapy , Cholangitis, Sclerosing/blood , Amine Oxidase (Copper-Containing)/blood , Amine Oxidase (Copper-Containing)/antagonists & inhibitors , Cell Adhesion Molecules/blood , Cell Adhesion Molecules/antagonists & inhibitors , Prospective Studies , Aged , Treatment Outcome , Young Adult , Alkaline Phosphatase/blood , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal/adverse effects , AdolescentABSTRACT
Pneumocystis jirovecii is a ubiquitous, unicellular fungus that can cause pneumonia (PJP) in immunosuppressed individuals. We report the first case of PJP complicating upadacitinib use for ulcerative colitis. This report is of clinical relevance given the widespread uptake of JAK inhibition.
Subject(s)
Cholangitis, Sclerosing , Colitis, Ulcerative , Pneumocystis carinii , Pneumonia, Pneumocystis , Humans , Colitis, Ulcerative/drug therapy , Colitis, Ulcerative/complications , Pneumonia, Pneumocystis/chemically induced , Pneumonia, Pneumocystis/drug therapy , Cholangitis, Sclerosing/complications , Cholangitis, Sclerosing/drug therapy , Heterocyclic Compounds, 3-Ring/adverse effects , Male , Middle Aged , FemaleABSTRACT
Background: Primary sclerosing cholangitis (PSC) is a chronic liver disease marked by inflammation of the bile ducts and results in the development of strictures and fibrosis. A robust clinical correlation exists between PSC and inflammatory bowel disease (IBD). At present, published data are controversial, and it is yet unclear whether IBD drives or attenuates PSC. Methods: Mdr2-deficient mice or DDC-fed mice were used as experimental models for sclerosing cholangitis. Additionally, colitis was induced in mice with experimental sclerosing cholangitis, either through infection with Citrobacter rodentium or by feeding with DSS. Lastly, fibrosis levels were determined through FibroScan analysis in people with PSC and PSC-IBD. Results: Using two distinct experimental models of colitis and two models of sclerosing cholangitis, we found that colitis does not aggravate liver pathology, but rather reduces liver inflammation and liver fibrosis. Likewise, people with PSC-IBD have decreased liver fibrosis compared to those with PSC alone. Conclusions: We found evidence that intestinal inflammation attenuates liver pathology. This study serves as a basis for further research on the pathogenesis of PSC and PSC-IBD, as well as the molecular mechanism responsible for the protective effect of IBD on PSC development. This study could lead to the discovery of novel therapeutic targets for PSC.
Subject(s)
Cholangitis, Sclerosing , Colitis , Inflammatory Bowel Diseases , Humans , Animals , Mice , Cholangitis, Sclerosing/drug therapy , Inflammatory Bowel Diseases/pathology , Inflammation , Liver Cirrhosis/pathologyABSTRACT
INTRODUCTION: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease associated with inflammation, fibrosis, and destruction of intra- and extrahepatic bile ducts. Despite substantial recent advances in our understanding of PSC, the only proven treatment of PSC is liver transplantation. There is an urgent unmet need to find medical therapies for this disorder. AREAS COVERED: Multiple drugs are currently under evaluation as therapeutic options for this disease. This article summarizes the literature on the various novel therapeutic options that have been investigated and are currently under development for the treatment of PSC. EXPERT OPINION: In the next decade, more than one drug will likely be approved for the treatment of the disease, and we will be looking at combination therapies for the optimal management of the disease.
Subject(s)
Cholangitis, Sclerosing , Liver Transplantation , Humans , Cholangitis, Sclerosing/drug therapy , Cholangitis, Sclerosing/complications , Combined Modality TherapyABSTRACT
BACKGROUND: Data on oral vancomycin for primary sclerosing cholangitis (PSC)-associated inflammatory bowel disease (IBD) are limited. AIMS: Using data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity. METHODS: In this retrospective multi-centre cohort study, we matched vancomycin-treated and untreated patients (1:3) based on IBD duration at the time of primary outcome assessment. The primary outcome was Physician Global Assessment (PGA) of IBD clinical activity after 1 year (±6 months) of vancomycin. We used generalised estimating equations (GEE) to examine the association between vancomycin and PGA remission, adjusting for IBD type, severity and medication exposures. Secondary outcomes included serum labs and endoscopic remission (global rating of no activity) among those with available data and also analysed with GEE. RESULTS: 113 PSC-IBD patients received vancomycin (median age 12.7 years, 63% male). The matched cohort included 70 vancomycin-treated and 210 untreated patients. Vancomycin was associated with greater odds of IBD clinical remission (odds ratio [OR] 3.52, 95% CI 1.97-6.31; adjusted OR [aOR] 5.24, 95% CI 2.68-10.22). Benefit was maintained in sensitivity analyses restricted to non-transplanted patients and those with baseline moderate-severe PGA. Vancomycin was associated with increased odds of endoscopic remission (aOR 2.76, 95% CI 1.002-7.62; N = 101 with data), and with lower CRP (p = 0.03) and higher haemoglobin and albumin (both p < 0.01). CONCLUSION: Vancomycin was associated with greater odds of IBD clinical and endoscopic remission. Additional, preferably randomised, controlled studies are needed to characterise efficacy using objective markers of mucosal inflammation, and to examine safety and define optimal dosing.
Subject(s)
Anti-Bacterial Agents , Cholangitis, Sclerosing , Inflammatory Bowel Diseases , Vancomycin , Humans , Vancomycin/administration & dosage , Vancomycin/adverse effects , Cholangitis, Sclerosing/drug therapy , Cholangitis, Sclerosing/complications , Female , Male , Retrospective Studies , Child , Adolescent , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/adverse effects , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/complications , Administration, Oral , Treatment Outcome , Severity of Illness Index , Remission Induction , Cohort StudiesABSTRACT
An asymptomatic 77-year-old man with intrahepatic bile duct dilation was referred to our hospital. Cholangiography revealed alternations between strictures and dilated segments from the right and left hepatic ducts to the lower bile ducts, with findings of a pruned tree, beaded, shaggy appearance, and diverticulum-like outpouching. Histopathology revealed abundant immunoglobulin G4 (IgG4)-positive plasma cells (> 10 per high-power field) with an IgG4/IgG-positive cell ratio of 40-50%. After 2 weeks of steroid therapy, the cholangiography markedly improved. Because the cholangiographic findings resembled those of primary sclerosing cholangitis, steroid therapy proved useful in differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis.
Subject(s)
Cholangitis, Sclerosing , Male , Humans , Aged , Cholangitis, Sclerosing/diagnostic imaging , Cholangitis, Sclerosing/drug therapy , Bile Ducts/diagnostic imaging , Bile Ducts/pathology , Cholangiography , Immunoglobulin G , Steroids , Diagnosis, DifferentialSubject(s)
Anti-Bacterial Agents , Cholangitis, Sclerosing , Inflammatory Bowel Diseases , Vancomycin , Humans , Cholangitis, Sclerosing/drug therapy , Cholangitis, Sclerosing/complications , Vancomycin/adverse effects , Vancomycin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/adverse effects , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/complications , Female , Male , Middle Aged , AdultABSTRACT
BACKGROUND: Primary sclerosing cholangitis (PSC) is an immune-mediated, chronic cholestatic liver disease. Currently, liver transplantation is the only established life-saving treatment. Several studies have evaluated the effect of different biologic therapies on PSC with inconclusive findings. We conducted a systematic review and meta-analysis to assess the effects of biologics in PSC and associated inflammatory bowel disease (IBD). METHODS: MEDLINE, Scopus, and Embase were searched up to July 31, 2023, for studies reporting the effects of biologics in patients with PSC-IBD. Effects of biologic therapy on alkaline phosphatase, total bilirubin, ulcerative colitis response score, and adverse events were calculated and expressed as standardized difference of means (SMD), proportions, and 95% CI using a random-effects model. RESULTS: Six studies, including 411 PSC-IBD patients who received biologics, were included. Biologic treatment was associated with no change in alkaline phosphatase (SMD: 0.1, 95% CI: -0.07 -0.17, p=0.43), but a small and statistically significant increase in total bilirubin (SMD: 0.2, 95% CI: 0.05-0.35, p<0.01). 31.2% (95% CI: 23.8-39.7) of patients with IBD achieved endoscopic response, and there was a significant improvement in ulcerative colitis response score (SMD: -0.6,95% CI: -0.88 to 0.36, p<0.01). Furthermore, 17.6% (95% CI: 13.0-23.5) of patients experienced adverse events severe enough to discontinue therapy, and 29.9% (95% CI: 25.2-34.8) had a loss of response to biologics. CONCLUSIONS: Treatment of patients with PSC-IBD with biologics (vedolizumab, infliximab, and adalimumab) was not associated with improvement of biochemical markers of cholestasis. Biologics are effective in treating the colitis associated with PSC. Vedolizumab was associated with worsening liver enzymes in contrast to other biologics, a finding that warrants further study.
Subject(s)
Biological Products , Cholangitis, Sclerosing , Cholestasis , Colitis, Ulcerative , Inflammatory Bowel Diseases , Humans , Colitis, Ulcerative/drug therapy , Alkaline Phosphatase , Cholangitis, Sclerosing/complications , Cholangitis, Sclerosing/drug therapy , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/drug therapy , Bilirubin , Biological Products/adverse effectsABSTRACT
BACKGROUND: Autoimmune liver diseases (AILD) are increasing and common forms of chronic liver disease (CLD) with different clinical responses and characteristics which can result in cirrhosis. This study aimed to investigate the natural history and characteristics of AILD in an Iranian population. METHODS: Patients with AILD [Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC) and Overlap Syndrome (OS)] referred to Middle East Liver Diseases (MELD) center, Tehran, Iran, between January 2002 and December 2022 were included in this retrospective cohort study. The main features of natural history (the trends of liver functional tests (LFT), Auto-Antibodies, response to treatment and cirrhotic status) along with demographic data were studied. RESULTS: Two hundred sixty-five patients (160 (60.4%) AIH, 37 (14.0%) PBC, 20 (7.5%) PSC, 48 (18.1%) overlap syndrome) with a median follow-up time of 5 years (IQR 4 to 8 years) were included. Baseline laboratory tests revealed that patients with AIH exhibit elevated transaminase levels. However, patients suffering from PBC and PSC displayed increased alkaline phosphatase levels. Conversely, in overlap syndrome patients, both transaminases and alkaline phosphatase were observed at high levels. Autoantibodies represented themselves as important diagnostic markers for the AIH and PBC but not for PSC. The complete response occurred in 112 (70%) of and 28 (58.4%) patients with AIH and overlap syndrome respectively and 21 patients 11 (6.9%) of AIH and 10 (20.8%) of overlap syndrome) were non-responders. Other patients in these two categories were considered as insufficient responders. On the other side, 32 (91.9%) and 8 (40%) of patients with PBC and PSC biochemically responded to Ursodeoxycholic Acid (UDCA). Unpredictably, cirrhosis regression was observed in some AIH and PBC patients. CONCLUSION: Appropriate medication management for AILD patients may leads to regression from cirrhosis and improvement of manifestations; while discontinuation of medication may cause relapses. However, patient suffering from PSC showed limited response to treatment.
Subject(s)
Autoimmune Diseases , Cholangitis, Sclerosing , Hepatitis, Autoimmune , Liver Cirrhosis, Biliary , Liver Diseases , Humans , Liver Cirrhosis, Biliary/diagnosis , Liver Cirrhosis, Biliary/drug therapy , Retrospective Studies , Alkaline Phosphatase , Iran , Hepatitis, Autoimmune/complications , Hepatitis, Autoimmune/diagnosis , Hepatitis, Autoimmune/drug therapy , Liver Cirrhosis , Cholangitis, Sclerosing/complications , Cholangitis, Sclerosing/diagnosis , Cholangitis, Sclerosing/drug therapySubject(s)
Humans , Male , Adolescent , Vancomycin/therapeutic use , Cholangitis, Sclerosing/complications , Cholangitis, Sclerosing/drug therapy , Cholangitis, Sclerosing/therapy , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/therapyABSTRACT
INTRODUÇÃO: A colangite biliar primária (CBP) é uma doença hepática autoimune colestática rara, caracterizada por inflamação e destruição progressiva dos ductos interlobulares de pequeno e médio calibre, colestase que provoca fadiga e prurido debilitantes, podendo evoluir para fibrose, cirrose, doença hepática terminal e morte. Estudos epidemiológicos de base populacional de diversos países mostrou taxas de incidência que variam de 0,33 a 5,8 por 100 mil habitantes por ano e taxas de prevalência 1,91 a 40,2 por 100 mil habitantes por ano. Atualmente, o SUS oferece apenas alternativas para o tratamento dos sintomas da doença hepática terminal (cirrose), e não possui nenhuma alternativa terapêutica com idicação para CBP. TECNOLOGIA: Ácido Ursodesoxicólico (Ursacol®). PERGUNTA: O uso de ácido ursodesoxicólico (AUDC) é eficaz e seguro em pacientes com colangite biliar primária quando comparado às opções disponíveis atualmente no SUS? EVIDÊNCIAS CIENTÍFICAS: Com base nos critérios de inclusão, na estratégia de busca e nas referências dos artigos selecionados, foram incluídos 13 estudos, 10 já incluídos pelo demandante e três pela Secretaria-Executiva da CONITEC. Mortalidade foi avaliada por seis estudos, três observaram que não houve diferença estatisticamente significante entre AUDC e placebo, em outros três estudos os resultados foram variados. A sobrevida global foi avaliada por três estudos que concluíram que a sobrevida observada foi significativamente (P< 0.001) maior no grupo tratado com AUDC quando comparado ao previsto pelo modelo de Mayo ou grupo não tratado. Os resultados de sobrevida livre de transplante (SLT) de quatro estudos puderam ser meta-analisados, e o tratamento com AUDC apresentou aumento do tempo de SLT no acompanhamento de longo prazo a partir do quinto ano de tratamento, com resultados estatisticamente significantes para os anos 5, 8 e 10 (p< 0,01). Não houve diferença estatisticamente significantes nas meta-análises para proporção de eventos adversos graves quando se comparou AUDC com placebo/não tratamento. AVALIAÇÃO ECONÔMICA: O demandante delineou em sua proposta um estudo de custo-efetividade do AUDC como opção de tratamento em pacientes com CBP sintomáticos. O estudo demonstrou uma RCEI de R$ 9,32 mil por ano livre de transplante salvo e R$ 13,26 mil por ano de vida salvo, quando comparado ao placebo. O modelo possui limitações na fonte de dados de eficácia, no levantamento dos custos e no horizonte temporal usado no modelo que limitam a interpretação do resultado. AVALIAÇÃO DE IMPACTO ORÇAMENTÁRIO: A partir das premissas adotadas pelo demandante, o impacto orçamentário incremental com a incorporação do AUDC no SUS seria de R$11,77 milhões no primeiro ano e de R$98,52 milhões no acumulado de cinco anos. Entretanto, análise possui limitações quanto à estimativa da população e a previsão de custos. MONITORAMENTO DO HORIZONTE TECNOLÓGICO: As buscas apontaram haver quatro potenciais medicamentos nas fases 3 ou 4 de desenvolvimento clínico para a indicação terapêutica considerada. Destes, o ácido obeticólico e selaldelpar lisina parecem estar num horizonte mais próximo, dado que obtiveram registro sanitário no FDA e/ou EMA nos últimos dois anos. RECOMENDAÇÃO DA CONITEC: Os membros presentes em sua 68º reunião ordinária, no dia 05 de julho de 2018, deliberaram que o tema fosse submetido à consulta pública com recomendação preliminar desfavorável à incorporação do AUDC para tratamento de pacientes com CBP. CONSULTA PÚBLICA: Foram recebidas 25 contribuições técnico-científicas e 140 contribuições de experiência e opinião durante o período de consulta pública, entre 04 de agosto a 23 de agosto de 2018. Dentre as contribuições, a maioria foram contrárias à recomendação da CONITEC. Os principais argumentos enviados pela empresa fabricante foram: alto custo do medicamento, única opção terapêutica para CBP, melhroa dos parâmetros hepáticos, recomendação de agências internacionais, mudança da história natural da doença e redução dos eventos adversos. O plenário da CONITEC entendeu a necessidade de modificar sua recomendação inicial e deliberaram, por unanimidade, por recomendar a incorporação no SUS do AUDC para CBP. DELIBERAÇÃO FINAL: Os membros da CONITEC presentes na 68ª reunião ordinária, no dia 04 de julho de 2018, deliberaram, por unanimidade, por recomendar a incorporação do AUDC para tratamento de pacientes com Colangite Biliar Primária. Foi assinado o Registro de Deliberação nº 355/2018. DECISÃO: A Portaria nº 47, de 16 de outubro de 2017, tornou pública a decisão de incorporar o ácido ursodesoxicólico para colangite biliar, no âmbito do Sistema Único deSaúde - SUS. Publicada no Diário Oficial da União nº 200, seção 1, página 44.